ClinicalTrials.gg
RecruitingNCT06608446LINFOUpdated Apr 21, 2026

Effects of a Telerehabilitation Intervention in the Management of Complications After Breast Cancer Surgery

An interventional study of Telerehabilitation and Standard Care in Breast Neoplasms, sponsored by Fondazione Policlinico Universitario Campus Bio-Medico. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Fondazione Policlinico Universitario Campus Bio-Medico · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 4 months after the study started (first participant enrolled May 2023, registered Sep 2024).
  • Started May 2023; still recruiting 3 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The most common complaints after breast surgery are postoperative pain reported in up to 68% of patients, musculoskeletal problems in the shoulder and functional limitations in up to 59% of patients after mastectomy and quadrantectomy, reduction in range of motion ( ROM) in 24-53% and strength deficit.

The study aims to verify the effectiveness of a telerehabilitation treatment in terms of prevention of possible complications following breast cancer surgery.

Primary objective: to examine whether the group of patients undergoing rehabilitation surgery in the immediate post-operative period shows a reduction in the onset of complications compared to the group of patients who followed standard procedures.

Secondary objective: to study any preoperative prognostic factors for the onset of complications, to study the effectiveness of the rehabilitation treatment in terms of reduction of painful symptoms, improvement of joint ROM, muscle strength and perceived quality of life.

Read the detailed description

Breast cancer is the most common malignancy in women worldwide. Advances in early detection and improved treatment of breast cancer have led to increased survival after diagnosis, resulting in many more women living with the consequences of cancer treatment.

Breast cancer surgeries and treatments can cause arm morbidity that can progress beyond 2.5 years.

The most common complaints after breast surgery are postoperative pain reported in up to 68% of patients, musculoskeletal problems in the shoulder and functional limitations in up to 59% of patients after mastectomy and quadrantectomy, reduction in range of motion ( ROM) in 24-53% and strength deficit.

Other complications include postoperative axillary web syndrome (AWS), which can cause pain and movement limitations; lymphedema reported with a prevalence of 6-52% especially after axillary lymph node dissection (ALND); kinematic alterations that may promote future development of rotator cuff disease; scapulohumeral dyskinesia, proprioception deficit, postural alterations and reduced quality of life.

There is scientific evidence in the literature to suggest that early postoperative exercise is safe and can improve shoulder function; however, uncertainty remains about the optimal content, timing, and cost-effectiveness of exercise interventions.

The study aims to verify the effectiveness of a rehabilitation treatment in terms of prevention of possible complications following breast cancer surgery.

Primary objective: to examine whether the group of patients undergoing rehabilitation surgery in the immediate post-operative period shows a reduction in the onset of complications compared to the group of patients who followed standard procedures.

Secondary objective: to study any preoperative prognostic factors for the onset of complications, to study the effectiveness of the rehabilitation treatment in terms of reduction of painful symptoms, improvement of joint ROM, muscle strength and perceived quality of life.

02

Conditions studied

  • Breast Neoplasms

Browse trials for

03

In context

Breast Neoplasms

14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 155 is above the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Fondazione Policlinico Universitario Campus Bio-Medico is the lead sponsor of 29 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of breast cancer
  • Having undergone quadrantectomy or mastectomy surgery
  • Age > 18 years
  • Signature of

Exclusion criteria

Exclusion Criteria:

  • Neurological deficits with sensorimotor impairment of the upper limb
  • Cognitive deficits that prevent the completion of questionnaires (>24)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Telerehabilitation

    In the days following surgery, intervention group will receive a structured rehabilitation session by a physiotherapist. In this session, two booklets will be provided to the patients, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid their possible onset through the demonstration of exercises to be carried out at home, self-massage techniques of the scar, behaviors and lifestyle to be adopted immediately after surgery. This group will carry out, starting from 10 days post-surgery, a home tele-rehabilitation intervention from Monday to Friday via the TeleHab device (Vald Performance) until 2 months after surgery. Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week.

    Other: Telerehabilitation

  • Active comparator
    Standard care

    Standard care consists of the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out which generally consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.

    Other: Standard Care

Interventions

  • OtherTelerehabilitation

    The telerehabilitation intervention will begin from 10 days post-surgery, the operation will be carried out at home from Monday to Friday via the TeleHab device (Vald Performance) up to 2 months after the surgery. Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week. The progression of the exercises will be carried out taking into account the pain and fatigue recorded by the patient at the end of each exercise session.

  • OtherStandard Care

    Standard care intervention follow the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out. It consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.

06

What researchers measure

Primary outcomes

  1. Complications

    Number of complications (i.e. axyllary web syndrome; lymphedema; persistent pain)

    Time frame: 7-10 days after surgery

  2. Complications

    Number of complications (i.e. axyllary web syndrome; lymphedema)

    Time frame: 2 months after surgery

  3. Complications

    Number of complications (i.e. axyllary web syndrome; lymphedema)

    Time frame: 6 months after surgery

Secondary outcomes

  1. Upper limb pain

    Pain assessed through the numeric pain rating scale (0-10)

    Time frame: before surgery

  2. Upper limb pain

    Pain assessed through the numeric pain rating scale (0-10)

    Time frame: 7-10 days after surgery

  3. Upper limb pain

    Pain assessed through the numeric pain rating scale (0-10)

    Time frame: 2 months after surgery

  4. Upper limb pain

    Pain assessed through the numeric pain rating scale (0-10)

    Time frame: 6 months after surgery

  5. Neck Disability

    Neck related disability assessed through the questionnaire Neck Disabiltiy Index Value range (0% min disability - 100% max disability)

    Time frame: before surgery

  6. Neck Disability

    Neck related disability assessed through the questionnaire Neck Disability Index Value range (0% min disability - 100% max disability)

    Time frame: 7-10 days after surgery

  7. Neck Disability

    Neck related disability assessed through the questionnaire Neck Disability Index Value range (0% min disability - 100% max disability)

    Time frame: 2 months after surgery

  8. Neck Disability

    Neck related disability assessed through the questionnaire Neck Disability Index Value range (0% min disability - 100% max disability)

    Time frame: 6 months after surgery

  9. Upperlimb Disability

    Upperlimb related disability assessed through the questionnaire Disability of the arm, shoulder and hand (DASH) Value range (0% min disability - 100% max disability)

    Time frame: before surgery

  10. Upperlimb Disability

    Upperlimb related disability assessed through the questionnaire Disability of the arm, shoulder and hand (DASH) Value range (0% min disability - 100% max disability)

    Time frame: 7-10 days after surgery

  11. Upperlimb Disability

    Upperlimb related disability assessed through the questionnaire Disability of the arm, shoulder and hand (DASH) Value range (0% min disability - 100% max disability)

    Time frame: 2 months after surgery

  12. Upperlimb Disability

    Upperlimb related disability assessed through the questionnaire Disability of the arm, shoulder and hand (DASH) Value range (0% min disability - 100% max disability)

    Time frame: 6 months after surgery

  13. Self-reported Quality of life

    Impact on quality of life assessed through the questionnaire Short Form-36 Health Survey Value range (0 min QoL- 100 max QoL)

    Time frame: before surgery

  14. Self-reported Quality of life

    Impact on quality of life assessed through the questionnaire Short Form-36 Health Survey Value range (0 min QoL- 100 max QoL)

    Time frame: 7-10 days after surgery

  15. Self-reported Quality of life

    Impact on quality of life assessed through the questionnaire Short Form-36 Health Survey Value range (0 min QoL- 100 max QoL)

    Time frame: 2 months after surgery

  16. Self-reported Quality of life

    Impact on quality of life assessed through the questionnaire Short Form-36 Health Survey Value range (0 min QoL- 100 max QoL)

    Time frame: 6 months after surgery

  17. Joint range of motion

    upper limb and cervical range of motion assessed through digital goniometer

    Time frame: before surgery

  18. Joint range of motion

    upper limb and cervical range of motion assessed through digital goniometer

    Time frame: 7-10 days after surgery

  19. Joint range of motion

    upper limb and cervical range of motion assessed through digital goniometer

    Time frame: 2 months after surgery

  20. Joint range of motion

    upper limb and cervical range of motion assessed through digital goniometer

    Time frame: 6 months after surgery

  21. Muscle strength

    handgrip, shoulder and neck muscle strength assessed through handheld dynamometer

    Time frame: before surgery

  22. Muscle strength

    handgrip, shoulder and neck muscle strength assessed through handheld dynamometer

    Time frame: 7-10 days after surgery

  23. Muscle strength

    handgrip, shoulder and neck muscle strength assessed through handheld dynamometer

    Time frame: 2 months after surgery

  24. Muscle strength

    handgrip, shoulder and neck muscle strength assessed through handheld dynamometer

    Time frame: 6 months after surgery

07

Study locations

1 of 1 sites recruiting
  • Fondazione Policlinico Universitario Campus Bio-Medico
    Roma, Roma 00128, Italy
    Recruiting
    • Marco Bravi, DPT · Contact+390622541624
    • Fabio Santacaterina, DPT · Contact+390622541624
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2026, 36 months after the start.

Of 2,661 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 36 months is close to that.

Counting every sponsor, half of 2,771 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2024
First posted
Sep 23, 2024
StartActual
May 15, 2023
Primary completionEst.
May 30, 2026
CompletionEst.
Jul 30, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06608446
Lead sponsor
Fondazione Policlinico Universitario Campus Bio-Medico
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
May 15, 2023
Primary completion
May 30, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
Apr 21, 2026

Study contacts

Silvia Sterzi, MD
Contact
s.sterzi@policlinicocampus.it
+390622541624
Marco Bravi, DPT
Contact
m.bravi@policlinicocampus.it
+390622541646

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion